Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 29, 2025 08:00 ET | Source: Therini Bio, Inc.

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease
July 10, 2025 03:00 ET | Source: Vect-Horus

Secarna Pharmaceuticals et Vect-Horus annoncent un programme de recherche pour le transport ciblé des thérapies visant l’ARN pour traiter les maladies du système nerveux central.

Ce partenariat permet d'associer la technologie OligoCreator® de Secarna avec la plateforme VECTrans® de Vect-Horus, afin de rendre possible le transport systémique des oligonucléotides à travers la...
July 10, 2025 03:00 ET | Source: Vect-Horus

Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders

The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable systemic delivery of oligonucleotide therapies across the blood-brain barrierThis...
June 23, 2025 07:00 ET | Source: Denovo Biopharma

Denovo Biopharma LLC Enters into an Exclusive Out-License Agreement with Chuang Yi Global Asset Management Co., Ltd. for Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD) in Taiwan

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced that it has out-licensed its...
June 10, 2025 14:00 ET | Source: Bexorg

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Bexorg Announces Multi-Program Research Collaboration with Biohaven to Enhance New CNS Drug Discovery and Development
June 06, 2025 07:00 ET | Source: Denovo Biopharma

Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression

- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104...
May 09, 2025 16:30 ET | Source: Coave Therapeutics

Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases

New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal...
May 02, 2025 07:00 ET | Source: Metagenomi, Inc.

Metagenomi to Present at Upcoming Scientific Meetings

Metagenomi to Present at Upcoming Scientific Meetings
March 20, 2025 07:30 ET | Source: Plus Therapeutics Inc.

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
March 11, 2025 08:33 ET | Source: Kaerus Bioscience

Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome

Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.

Next Page keyboard_arrow_right